Dr. Julia E. Mcguinness, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Baylor College of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 80
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: Baylor College of Medicine
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 288562 -
Hematology & Oncology Physician
NY license 288562
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
Medical groups
- Trustees of Columbia University in The City of New York (2,296 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 80
- Services billed
- 453
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 105 | 24 |
| Established patient office or other outpatient visit, 40-54 minutes | 104 | 19 |
| Established patient office or other outpatient visit, 30-39 minutes | 64 | 38 |
| Established patient office or other outpatient visit, 20-29 minutes | 16 | 13 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in New York, NY | 109 |
| Exemestane | 67 |
| Tamoxifen Citrate Other prescribers in New York, NY | 31 |
| Letrozole Other prescribers in New York, NY | 22 |
| Verzenio (abemaciclib) | 20 |
| Ondansetron Hcl Other prescribers in New York, NY | 16 |
| Veozah (fezolinetant) | 12 |
| Prochlorperazine Maleate Other prescribers in New York, NY | 12 |
| Loperamide (loperamide hcl) Other prescribers in New York, NY | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 12 payments worth $4,255 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $3,781 |
|---|---|
| Daiichi Sankyo Inc. | $238 |
| Genentech USA, Inc. | $154 |
| Genentech, Inc. | $49.05 |
| AstraZeneca Pharmaceuticals LP | $31.95 |
| Consulting Fee | $2,800 |
|---|---|
| Travel and Lodging | $975 |
| Food and Beverage | $479 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Nov 10, 2025 | Consulting Fee KISQALI · Oncology | $2,800 |
| Novartis Pharmaceuticals Corporation Oct 6, 2025 | Travel and Lodging KISQALI · Oncology · travel to Fort Lauderdale, FL | $410 |
| Novartis Pharmaceuticals Corporation Oct 29, 2025 | Travel and Lodging KISQALI · Oncology · travel to Fort Lauderdale, FL | $350 |
| Novartis Pharmaceuticals Corporation Oct 6, 2025 | Travel and Lodging KESIMPTA · Neurology · travel to Fort Lauderdale, FL · in-kind | $215 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $125,146 in research payments for these studies, mostly to the institutions running them.
- (VELA) Study of BLU-222 in Advanced Solid Tumors
Sanofi US Services Inc. · Terminated · NCT05252416 - A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Jazz Pharmaceuticals Inc. - The COMPASSHER2 trials comprehensive use of pathologic response assessment to optimize therapy in HER2POSITIVE breast cancer COMPASSHER2 residual disease rd a doubleblinded phase iii randomized trial of TDM1 compared …
Pfizer Inc. - A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
Blueprint Medicines Corporation - A randomized phase 3 double-blinded study comparing the efficacy and s
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.